[go: up one dir, main page]

NO20024683L - Terapier med oppdelte doser som har vaskulirt skadende aktivitet - Google Patents

Terapier med oppdelte doser som har vaskulirt skadende aktivitet

Info

Publication number
NO20024683L
NO20024683L NO20024683A NO20024683A NO20024683L NO 20024683 L NO20024683 L NO 20024683L NO 20024683 A NO20024683 A NO 20024683A NO 20024683 A NO20024683 A NO 20024683A NO 20024683 L NO20024683 L NO 20024683L
Authority
NO
Norway
Prior art keywords
vascular damaging
divided dose
damaging activity
dose therapies
damaging agent
Prior art date
Application number
NO20024683A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024683D0 (no
Inventor
David Peter Davis
Original Assignee
Angiogene Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0007740A external-priority patent/GB0007740D0/en
Priority claimed from GB0013928A external-priority patent/GB0013928D0/en
Priority claimed from GB0014904A external-priority patent/GB0014904D0/en
Application filed by Angiogene Pharm Ltd filed Critical Angiogene Pharm Ltd
Publication of NO20024683D0 publication Critical patent/NO20024683D0/no
Publication of NO20024683L publication Critical patent/NO20024683L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO20024683A 2000-03-31 2002-09-30 Terapier med oppdelte doser som har vaskulirt skadende aktivitet NO20024683L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0007740A GB0007740D0 (en) 2000-03-31 2000-03-31 Combination therapy
GB0013928A GB0013928D0 (en) 2000-06-08 2000-06-08 Methods of treatment
GB0014904A GB0014904D0 (en) 2000-06-20 2000-06-20 Methods of treatment
PCT/GB2001/001329 WO2001074369A1 (fr) 2000-03-31 2001-03-27 Therapies en doses fractionnees ayant un effet de degradation vasculaire

Publications (2)

Publication Number Publication Date
NO20024683D0 NO20024683D0 (no) 2002-09-30
NO20024683L true NO20024683L (no) 2002-10-15

Family

ID=27255635

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024683A NO20024683L (no) 2000-03-31 2002-09-30 Terapier med oppdelte doser som har vaskulirt skadende aktivitet

Country Status (23)

Country Link
US (1) US20030055024A1 (fr)
EP (1) EP1272200B1 (fr)
JP (1) JP2003528921A (fr)
KR (1) KR20020084267A (fr)
CN (1) CN1422157A (fr)
AT (1) ATE298240T1 (fr)
AU (2) AU4258601A (fr)
BR (1) BR0109671A (fr)
CA (1) CA2402078A1 (fr)
CZ (1) CZ20023231A3 (fr)
DE (1) DE60111622T2 (fr)
EE (1) EE200200549A (fr)
ES (1) ES2243466T3 (fr)
HU (1) HUP0300576A3 (fr)
IL (1) IL151627A0 (fr)
IS (1) IS6555A (fr)
MX (1) MXPA02009603A (fr)
NO (1) NO20024683L (fr)
NZ (1) NZ534190A (fr)
PL (1) PL357282A1 (fr)
PT (1) PT1272200E (fr)
SK (1) SK13902002A3 (fr)
WO (1) WO2001074369A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent
GB0223379D0 (en) * 2002-10-09 2002-11-13 Angiogene Pharm Ltd Combination therapy
FR2848212B1 (fr) * 2002-12-06 2006-10-27 Aventis Pharma Sa Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation
JP2006527753A (ja) * 2003-06-18 2006-12-07 アンギオジェン・ファーマシューティカルズ・リミテッド 結腸直腸癌などの治療のための、血管損傷効果を有する、５−ｆｕ、ｃｐｔ−１１または５−ｆｕおよびｃｐｔ−１１と組み合わせたｚｄ６１２６を含んでなる組成物
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL67646A0 (en) * 1982-01-15 1983-05-15 Lilly Co Eli Ascorbic acid ethers and related compounds
US4996237A (en) * 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
DE69105495T2 (de) * 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US6194439B1 (en) * 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
JPH11228594A (ja) * 1998-02-16 1999-08-24 Meiji Milk Prod Co Ltd 新規プロゲステロン化合物
ATE324888T1 (de) * 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
US20040067255A1 (en) * 2002-10-07 2004-04-08 Chaplin David J. Method of administering split doses of a vascular targeting agent

Also Published As

Publication number Publication date
IS6555A (is) 2002-10-18
AU4258601A (en) 2001-10-15
SK13902002A3 (sk) 2003-05-02
KR20020084267A (ko) 2002-11-04
US20030055024A1 (en) 2003-03-20
CA2402078A1 (fr) 2001-10-11
CZ20023231A3 (cs) 2003-01-15
DE60111622D1 (de) 2005-07-28
ATE298240T1 (de) 2005-07-15
DE60111622T2 (de) 2006-05-18
WO2001074369A1 (fr) 2001-10-11
ES2243466T3 (es) 2005-12-01
HUP0300576A3 (en) 2005-02-28
IL151627A0 (en) 2003-04-10
JP2003528921A (ja) 2003-09-30
HUP0300576A2 (hu) 2003-07-28
PL357282A1 (en) 2004-07-26
BR0109671A (pt) 2003-02-04
PT1272200E (pt) 2005-09-30
NZ534190A (en) 2007-05-31
EE200200549A (et) 2004-02-16
EP1272200B1 (fr) 2005-06-22
MXPA02009603A (es) 2004-05-14
NO20024683D0 (no) 2002-09-30
CN1422157A (zh) 2003-06-04
AU2001242586B2 (en) 2004-12-16
EP1272200A1 (fr) 2003-01-08

Similar Documents

Publication Publication Date Title
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
IL189546A0 (en) Therapy for the treatment of disease
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
EE200200107A (et) Kiire algtoimega selektiivse serotoniini tagasihaaramise inhibiitori kasutamine ravimi valmistamiseks, mis on ette nähtud seksuaalse funktsioonihäireravimiseks
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
NO20024683L (no) Terapier med oppdelte doser som har vaskulirt skadende aktivitet
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
ATE316960T1 (de) Pyrazolidinol-verbindungen
PT1183046E (pt) Derivado de aminotetralina para a terapia de doencas cardiovasculares
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
DE60235965D1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
MX2024007451A (es) Metodos de tratamiento de enfermedades neoplasicas.
ATE337826T1 (de) Simplifizierte sarcodictyn-derivate als anti- tumor-mittel
RU2002129097A (ru) Комбинированные терапии с использованием активности, повреждающей сосуды